Ritalin vs Adderall
MEDICATION COMPARISON · FROM FDA LABELS AND HEAD-TO-HEAD STUDIES
Reviewed by Tariq Halim, MD · Last medical review: November 12, 2026 · Editorial policy
Side-by-side facts (from each FDA label)
Each cell is copied from that product’s key facts, which cite its current FDA prescribing information. Durations and doses come from each product’s own label studies; they are not a head-to-head comparison.
| Ritalin | Adderall | |
|---|---|---|
| Drug class | CNS Stimulant · Methylphenidates | CNS Stimulant · Amphetamines |
| Active ingredient | methylphenidate hydrochloride | dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate |
| Approved or studied ages (label) | ADHD in children 6 years and older and adults; narcolepsy | ADHD: 3 years and older (not recommended under 3); also narcolepsy |
| Form and strengths | Immediate-release tablet; 5 mg, 10 mg (scored), 20 mg (scored) tablets | Tablet; 5, 7.5, 10, 12.5, 15, 20, 30 mg tablets |
| Usual dose and maximum (label) | Children: start 5 mg twice daily; adults: average 20–30 mg/day in divided doses; maximum 60 mg/day. | Ages 3–5: start 2.5 mg daily; 6 and older: start 5 mg once or twice daily; only rarely above 40 mg/day. |
| Duration (label) | Each dose usually helps for about 3–4 hours; the label gives no exact duration. | No fixed duration in the label; doses are given 4–6 hours apart (peak about 3 hours). |
| DEA schedule | Schedule II controlled substance (CII) | Schedule II controlled substance (CII) |
| Generic | Generic available (see Generic manufacturers) | Generic available (see Generic manufacturers) |
| Label date | Prescribing Information revised 02/2025 (DailyMed) | Prescribing Information revised 05/2024 (DailyMed) |
| Availability (site status, Oct 2026) | Brand available | Shortage listed · sources differ on brand status |
Main differences in plain words
- Ritalin contains methylphenidate hydrochloride; Adderall contains dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate.
- Form: Ritalin: immediate-release tablet; Adderall: tablet.
- Controlled status: both: Schedule II controlled substance (CII).
- Generic: Ritalin: Generic available; Adderall: Generic available.
What studies compare them
The studies below include at least one direct (head-to-head) comparison of Ritalin and Adderall or their active formulations. Only head-to-head trials, analyses of them and network meta-analyses are used for comparisons on this page; read the note under each study for what it can and cannot show.
-
Immediate-release methylphenidate and Adderall (children 6–12)
In a summer treatment program, one morning dose of immediate-release methylphenidate tended to wear off in the early to mid afternoon, while one morning dose of Adderall lasted the school-day period, about as well as two doses of methylphenidate. Some children did well all day on one methylphenidate dose.
Direct comparison of immediate-release methylphenidate (the medicine in Ritalin) and Adderall in a small summer-program study.
Within-subject placebo-controlled crossover, 21 children (6–12 y) in an intensive summer treatment program; MPH 0.3 mg/kg once, twice or three times daily vs Adderall 0.3 mg/kg once or twice, with 3:30 PM dose-response conditions. A single AM Adderall dose matched twice-daily MPH through the 8:00 AM–3:30 PM period; a single AM MPH dose was less effective and seemed to wear off in the early to mid-afternoon (some children were maintained all day). Context: alongside intensive behavioral treatment.
Pelham WE, Gnagy EM, Chronis AM, et al. (1999). A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 104(6):1300-11. DOI · PubMed 10585981
-
ADHD medicines (class)
A large analysis of 133 short-term trials found that every ADHD medicine studied worked better than placebo on clinician ratings in children and teens. Amphetamines had the largest average effect, and methylphenidate was the only medicine also shown to beat placebo on teacher ratings. Amphetamines and guanfacine led to more stopping for side effects than placebo in children. Weighing benefit and side effects, the authors favored methylphenidate first in children and amphetamines first in adults. There was too little data to judge effects beyond about 12 weeks.
Class-level comparison of methylphenidate and amphetamines.
Network meta-analysis of 133 double-blind RCTs (efficacy near 12 wk: 10,068 children/adolescents; 8,131 adults). Children, clinician-rated SMD vs placebo: amphetamines −1.02 (95% CI −1.19 to −0.85), methylphenidate −0.78 (−0.93 to −0.62), atomoxetine −0.56 (−0.66 to −0.45). Teacher-rated: only methylphenidate (−0.82, −1.16 to −0.48) and modafinil separated from placebo. Adults, clinician-rated: amphetamines −0.79 (−0.99 to −0.58), methylphenidate −0.49 (−0.64 to −0.35), atomoxetine −0.45 (−0.58 to −0.32). Discontinuation for adverse events vs placebo: amphetamines OR 2.30 (1.36–3.89) in children and 3.26 (1.54–6.92) in adults; guanfacine 2.64 (1.20–5.81) in children; atomoxetine 2.33 (1.28–4.25) and methylphenidate 2.39 (1.40–4.08) in adults only. Head-to-head clinician-rated efficacy favored amphetamines over methylphenidate, atomoxetine and modafinil. Insufficient data at 26 and 52 weeks.
Funding / affiliation: Non-industry (Stichting Eunethydis; UK NIHR Oxford Health BRC).
Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727-738. DOI · PubMed 30097390
Observational safety data
These are not head-to-head trials. The findings below come from observational studies — they look at what happened to people in everyday care. They are not randomized comparisons of Ritalin and Adderall, and they cannot prove that one medicine caused psychosis. They are shown here separately from the trial and network-meta-analysis results above.
In a large US study of teenagers and young adults starting a stimulant, a first episode of psychosis that was then treated with an antipsychotic was uncommon (about 1 in 660 people). It was reported about twice as often with amphetamine medicines such as Adderall as with methylphenidate such as Ritalin.
A later study of young people admitted to a psychiatric hospital also found higher odds of a first episode of psychosis or mania among those who had recently been prescribed an amphetamine, especially at higher doses. Recent methylphenidate use was not linked in that study. Because only hospitalized patients were compared, the results may not apply to everyone.
A 2025 review that pooled studies of this kind also found that psychosis was reported more often with amphetamines than with methylphenidate.
Talk to your prescriber if you or your family notice unusual thoughts, seeing or hearing things that are not there, or a sudden change in mood.
Observational only; not randomized comparisons and not evidence of cause. Figures are those already verified on this site (saved PubMed abstracts).
- Moran 2019 (N Engl J Med; PubMed 30893533 · DOI): propensity-matched cohort from two US commercial claims databases, 2004–2015; 221,846 patients aged 13–25 (110,923 methylphenidate starters matched with 110,923 amphetamine starters). New psychosis with an antipsychotic prescription: 343 episodes (106 [0.10%] methylphenidate vs 237 [0.21%] amphetamine); HR for amphetamine 1.65 (95% CI 1.31–2.09). The authors report new-onset psychosis in approximately 1 in 660 patients. Funded by the National Institute of Mental Health and others.
- Moran 2024 (Am J Psychiatry; PubMed 39262211 · DOI): case-control study of McLean Hospital electronic records, 2005–2019; 1,374 patients aged 16–35 hospitalized for a first episode of psychosis or mania vs 2,748 psychiatric-hospital controls. Past-month prescription amphetamine: aOR 2.68 (95% CI 1.90–3.77); doses above 30 mg dextroamphetamine equivalents associated with 5.28-fold increased odds; past-month methylphenidate aOR 0.91 (0.54–1.55). The authors note selection bias from using hospitalized controls.
- Salazar de Pablo 2025 (JAMA Psychiatry; PubMed 40900605 · DOI): systematic review and meta-analysis of 16 studies (N=391,043; mean age 12.6 years). Psychosis, amphetamines vs methylphenidate: OR 1.57 (95% CI 1.15–2.16; 3 studies, n=231,325). Pooled occurrence among stimulant-treated individuals: psychotic symptoms 2.76% (95% CI 0.73–9.88), psychotic disorder 2.29% (1.52–3.40), bipolar disorder 3.72% (0.77–16.05), with significant heterogeneity (I2 >95%). Observational data; causality not established.
Switching between them (label)
What each FDA label says about starting it after another medicine. Switch the clinician view on to see the full label wording and any dose tables. More in the switching guide.
Ritalin: the label (section 2) gives no switching or conversion instruction.
Adderall: the label (section 2) gives no switching or conversion instruction. The label (no revision date shown on DailyMed) lists the amphetamine base content of each tablet strength but gives no switching instruction.
For clinicians
Label facts are from each product’s current prescribing information (Ritalin: revised 02/2025; Adderall: revised 05/2024). Evidence summaries show the study detail and funding; comparative statements are limited to head-to-head trials, analyses of them and network meta-analyses. Indirect comparisons (for example, matching-adjusted indirect comparisons) are not used for efficacy claims.
Talk to your prescriber. These two medicines are not interchangeable at the same dose unless a label says so. Bring this page to your appointment if it helps, but do not change, stop or swap medicines on your own.
Frequently asked questions
What is the difference between Ritalin and Adderall?
Ritalin contains methylphenidate hydrochloride (immediate-release tablet); Adderall contains dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate (tablet). Ritalin: Schedule II controlled substance (CII). Adderall: Schedule II controlled substance (CII). The side-by-side table on this page lists approved ages, doses, duration and generic status from each label.
Is Ritalin more effective than Adderall?
Pelham 1999: In a summer treatment program, one morning dose of immediate-release methylphenidate tended to wear off in the early to mid afternoon, while one morning dose of Adderall lasted the school-day period, about as well as two doses of methylphenidate. Some children did well all day on one methylphenidate dose. Results from one study population may not apply to every patient; the best choice depends on the person.
Which lasts longer, Ritalin or Adderall?
Per the labels: Ritalin: Each dose usually helps for about 3–4 hours; the label gives no exact duration. Adderall: No fixed duration in the label; doses are given 4–6 hours apart (peak about 3 hours). These figures come from separate label studies, not from one study comparing the two. In a head-to-head study (Pelham 1999): In a summer treatment program, one morning dose of immediate-release methylphenidate tended to wear off in the early to mid afternoon, while one morning dose of Adderall lasted the school-day period, about as well as two doses of methylphenidate. Some children did well all day on one methylphenidate dose.
Can you switch from Ritalin to Adderall?
Neither label gives a milligram conversion between these two products. Ritalin label: no switching or conversion instruction in section 2. Adderall label: no switching or conversion instruction in section 2. Any switch is planned and adjusted by the prescriber.
Are Ritalin and Adderall available as generics?
Ritalin: Generic available. Adderall: Generic available. Current supply is tracked on the availability tracker page.
Sources
- Sandoz Inc. Ritalin (methylphenidate hydrochloride) tablets, CII. Prescribing Information, revised 02/2025. DailyMed (accessed Oct 2026).
- Teva Pharmaceuticals USA, Inc. Adderall (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets), CII. Prescribing Information, revised 05/2024 (Rev. O). DailyMed (accessed Oct 2026).
- Pelham WE, Gnagy EM, Chronis AM, et al. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 1999;104(6):1300-11. PubMed
- Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. PubMed
- Moran LV, Ongur D, Hsu J, et al. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. N Engl J Med. 2019;380(12):1128-1138. PubMed · DOI
- Moran LV, Skinner JP, Shinn AK, et al. Risk of Incident Psychosis and Mania With Prescription Amphetamines. Am J Psychiatry. 2024;181(10):901-909. PubMed · DOI
- Salazar de Pablo G, Aymerich C, Chart-Pascual JP, et al. Occurrence of Psychosis and Bipolar Disorder in Individuals With Attention-Deficit/Hyperactivity Disorder Treated With Stimulants: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025;82(11):1103-1112. PubMed · DOI